Published in J Med Chem on May 19, 2005
Varenicline Augmentation of Patch Outcomes in Heavy Drinkers' Smoking Cessation | NCT02859142
Human Laboratory Study of Varenicline and Bupropion for Nicotine Dependence (ChanBan) | NCT00749658
Efficacy and safety of varenicline for smoking cessation in patients with cardiovascular disease: a randomized trial. Circulation (2010) 4.50
Drug-evoked synaptic plasticity in addiction: from molecular changes to circuit remodeling. Neuron (2011) 3.93
Effect of varenicline on smoking cessation through smoking reduction: a randomized clinical trial. JAMA (2015) 3.56
Pharmacology of nicotine: addiction, smoking-induced disease, and therapeutics. Annu Rev Pharmacol Toxicol (2009) 2.90
Combination treatment with varenicline and bupropion in an adaptive smoking cessation paradigm. Am J Psychiatry (2014) 2.90
It is not "either/or": activation and desensitization of nicotinic acetylcholine receptors both contribute to behaviors related to nicotine addiction and mood. Prog Neurobiol (2007) 2.85
Varenicline for tobacco dependence. N Engl J Med (2008) 2.70
Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, selectively decreases ethanol consumption and seeking. Proc Natl Acad Sci U S A (2007) 2.68
Innate C-H trifluoromethylation of heterocycles. Proc Natl Acad Sci U S A (2011) 2.52
Varenicline improves mood and cognition during smoking abstinence. Biol Psychiatry (2008) 2.29
Varenicline reduces alcohol self-administration in heavy-drinking smokers. Biol Psychiatry (2009) 2.25
Nicotine binding to brain receptors requires a strong cation-pi interaction. Nature (2009) 2.21
Effects of varenicline and bupropion sustained-release use plus intensive smoking cessation counseling on prolonged abstinence from smoking and on depression, negative affect, and other symptoms of nicotine withdrawal. JAMA Psychiatry (2013) 2.11
Nicotine dependence pharmacogenetics: role of genetic variation in nicotine-metabolizing enzymes. J Neurogenet (2009) 2.07
Cognitive enhancement as a pharmacotherapy target for stimulant addiction. Addiction (2010) 2.04
Partial agonists of the α3β4* neuronal nicotinic acetylcholine receptor reduce ethanol consumption and seeking in rats. Neuropsychopharmacology (2010) 1.99
Stopping smokeless tobacco with varenicline: randomised double blind placebo controlled trial. BMJ (2010) 1.93
Effect of varenicline and bupropion SR on craving, nicotine withdrawal symptoms, and rewarding effects of smoking during a quit attempt. Psychopharmacology (Berl) (2007) 1.92
Nicotine receptors and depression: revisiting and revising the cholinergic hypothesis. Trends Pharmacol Sci (2010) 1.71
Cytisine, a partial agonist of high-affinity nicotinic acetylcholine receptors, has antidepressant-like properties in male C57BL/6J mice. Neuropharmacology (2007) 1.63
Pre-clinical properties of the alpha4beta2 nicotinic acetylcholine receptor partial agonists varenicline, cytisine and dianicline translate to clinical efficacy for nicotine dependence. Br J Pharmacol (2010) 1.59
Effects of varenicline on smoking cue–triggered neural and craving responses. Arch Gen Psychiatry (2011) 1.45
Therapeutic advances in the treatment of nicotine addiction: present and future. Ther Adv Chronic Dis (2010) 1.42
Cholinergic modulation of locomotion and striatal dopamine release is mediated by alpha6alpha4* nicotinic acetylcholine receptors. J Neurosci (2010) 1.41
Modulation of ethanol consumption by genetic and pharmacological manipulation of nicotinic acetylcholine receptors in mice. Psychopharmacology (Berl) (2010) 1.37
Structural differences determine the relative selectivity of nicotinic compounds for native alpha 4 beta 2*-, alpha 6 beta 2*-, alpha 3 beta 4*- and alpha 7-nicotine acetylcholine receptors. Neuropharmacology (2010) 1.37
Effects of moderate-dose treatment with varenicline on neurobiological and cognitive biomarkers in smokers and nonsmokers with schizophrenia or schizoaffective disorder. Arch Gen Psychiatry (2011) 1.33
Effects of the nicotinic receptor partial agonists varenicline and cytisine on the discriminative stimulus effects of nicotine in rats. Pharmacol Biochem Behav (2008) 1.31
Effects of nicotine in experimental animals and humans: an update on addictive properties. Handb Exp Pharmacol (2009) 1.31
Varenicline attenuates cue-induced relapse to alcohol, but not nicotine seeking, while reducing inhibitory response control. Psychopharmacology (Berl) (2011) 1.31
α6β2* and α4β2* nicotinic acetylcholine receptors as drug targets for Parkinson's disease. Pharmacol Rev (2011) 1.29
Activation of alpha4* nAChRs is necessary and sufficient for varenicline-induced reduction of alcohol consumption. J Neurosci (2010) 1.28
A preliminary investigation of varenicline for heavy drinking smokers. Psychopharmacology (Berl) (2011) 1.27
Modulation of ethanol drinking-in-the-dark by mecamylamine and nicotinic acetylcholine receptor agonists in C57BL/6J mice. Psychopharmacology (Berl) (2009) 1.26
The alpha4beta2 nicotinic acetylcholine-receptor partial agonist varenicline inhibits both nicotine self-administration following repeated dosing and reinstatement of nicotine seeking in rats. Psychopharmacology (Berl) (2009) 1.24
Varenicline, a partial agonist at neuronal nicotinic acetylcholine receptors, reduces nicotine-induced increases in 20% ethanol operant self-administration in Sprague-Dawley rats. Addict Biol (2011) 1.21
Genetics of nicotine dependence and pharmacotherapy. Biochem Pharmacol (2007) 1.21
Prescription drugs associated with reports of violence towards others. PLoS One (2010) 1.21
Adjunctive varenicline treatment with antipsychotic medications for cognitive impairments in people with schizophrenia: a randomized double-blind placebo-controlled trial. Neuropsychopharmacology (2011) 1.20
Varenicline has antidepressant-like activity in the forced swim test and augments sertraline's effect. Eur J Pharmacol (2009) 1.19
Nicotinic pharmacophore: the pyridine N of nicotine and carbonyl of acetylcholine hydrogen bond across a subunit interface to a backbone NH. Proc Natl Acad Sci U S A (2010) 1.18
Nicotine aversion: Neurobiological mechanisms and relevance to tobacco dependence vulnerability. Neuropharmacology (2013) 1.18
Patterns of nicotinic receptor antagonism: nicotine discrimination studies. J Pharmacol Exp Ther (2011) 1.18
Recent advances in understanding nicotinic receptor signaling mechanisms that regulate drug self-administration behavior. Biochem Pharmacol (2011) 1.17
Dopamine transporter genotype modulation of neural responses to smoking cues: confirmation in a new cohort. Addict Biol (2011) 1.16
The safety and efficacy of varenicline in cocaine using smokers maintained on methadone: a pilot study. Am J Addict (2010) 1.15
Smoking cessation pharmacogenetics: analysis of varenicline and bupropion in placebo-controlled clinical trials. Neuropsychopharmacology (2011) 1.15
Population pharmacokinetic analysis of varenicline in adult smokers. Br J Clin Pharmacol (2009) 1.15
Genetic variability in nicotinic acetylcholine receptors and nicotine addiction: converging evidence from human and animal research. Behav Brain Res (2008) 1.14
Pharmacological characterization of the allosteric modulator desformylflustrabromine and its interaction with alpha4beta2 neuronal nicotinic acetylcholine receptor orthosteric ligands. J Pharmacol Exp Ther (2010) 1.11
Varenicline is a potent agonist of the human 5-hydroxytryptamine3 receptor. J Pharmacol Exp Ther (2011) 1.10
A randomized placebo-controlled trial of varenicline for smoking cessation allowing flexible quit dates. Nicotine Tob Res (2011) 1.10
Neuronal nicotinic acetylcholine receptors: common molecular substrates of nicotine and alcohol dependence. Front Psychiatry (2013) 1.10
Decreased withdrawal symptoms but normal tolerance to nicotine in mice null for the alpha7 nicotinic acetylcholine receptor subunit. Neuropharmacology (2007) 1.10
An overview of the synthetic routes to the best selling drugs containing 6-membered heterocycles. Beilstein J Org Chem (2013) 1.09
Nicotinic receptor-based therapeutics and candidates for smoking cessation. Biochem Pharmacol (2009) 1.09
Activation and inhibition of mouse muscle and neuronal nicotinic acetylcholine receptors expressed in Xenopus oocytes. J Pharmacol Exp Ther (2010) 1.08
Neuropharmacology of the interoceptive stimulus properties of nicotine. Curr Drug Abuse Rev (2009) 1.07
Nicotinic receptor agonists decrease L-dopa-induced dyskinesias most effectively in partially lesioned parkinsonian rats. Neuropharmacology (2011) 1.07
Pharmacokinetics of the novel nicotinic receptor antagonist N,N'-dodecane-1,12-diyl-bis-3-picolinium dibromide in the rat. Drug Metab Dispos (2008) 1.07
Brain nicotinic acetylcholine receptor availability and response to smoking cessation treatment: a randomized trial. JAMA Psychiatry (2014) 1.06
What do we know about the role of pharmacotherapy for smoking cessation before or during pregnancy? Nicotine Tob Res (2009) 1.06
Neuronal nicotinic acetylcholine receptors as pharmacotherapeutic targets for the treatment of alcohol use disorders. CNS Neurol Disord Drug Targets (2010) 1.06
Varenicline is a potent partial agonist at α6β2* nicotinic acetylcholine receptors in rat and monkey striatum. J Pharmacol Exp Ther (2012) 1.05
Molecular actions of smoking cessation drugs at α4β2 nicotinic receptors defined in crystal structures of a homologous binding protein. Proc Natl Acad Sci U S A (2012) 1.04
Varenicline in the treatment of tobacco dependence. Neuropsychiatr Dis Treat (2008) 1.03
Nicotinic mechanisms influencing synaptic plasticity in the hippocampus. Acta Pharmacol Sin (2009) 1.01
Cholinergic functioning in stimulant addiction: implications for medications development. CNS Drugs (2009) 1.01
How can we use our knowledge of alcohol-tobacco interactions to reduce alcohol use? Annu Rev Clin Psychol (2012) 1.01
Targeting reward-relevant nicotinic receptors in the discovery of novel pharmacotherapeutic agents to treat tobacco dependence. Nebr Symp Motiv (2009) 1.00
Varenicline attenuates nicotine-enhanced brain-stimulation reward by activation of alpha4beta2 nicotinic receptors in rats. Neuropharmacology (2009) 1.00
Cognitive deficits in schizophrenia: focus on neuronal nicotinic acetylcholine receptors and smoking. Cell Mol Neurobiol (2007) 0.99
The role of the habenula in drug addiction. Front Hum Neurosci (2014) 0.98
Variations in binding among several agonists at two stoichiometries of the neuronal, α4β2 nicotinic receptor. J Am Chem Soc (2012) 0.98
Intravenous nicotine self-administration and cue-induced reinstatement in mice: effects of nicotine dose, rate of drug infusion and prior instrumental training. Neuropharmacology (2011) 0.98
Effects of varenicline on the reinforcing and discriminative stimulus effects of cocaine in rhesus monkeys. J Pharmacol Exp Ther (2011) 0.98
Pharmacologic characterization of a nicotine-discriminative stimulus in rhesus monkeys. J Pharmacol Exp Ther (2012) 0.98
Structural characterization of binding mode of smoking cessation drugs to nicotinic acetylcholine receptors through study of ligand complexes with acetylcholine-binding protein. J Biol Chem (2012) 0.98
Region-specific effects of N,N'-dodecane-1,12-diyl-bis-3-picolinium dibromide on nicotine-induced increase in extracellular dopamine in vivo. Br J Pharmacol (2007) 0.97
Effects of 21 days of varenicline versus placebo on smoking behaviors and urges among non-treatment seeking smokers. J Psychopharmacol (2012) 0.97
Comparison of the reinforcing properties of nicotine and cigarette smoke extract in rats. Neuropsychopharmacology (2014) 0.96
Varenicline, low dose naltrexone, and their combination for heavy-drinking smokers: human laboratory findings. Psychopharmacology (Berl) (2014) 0.95
Localized low-level re-expression of high-affinity mesolimbic nicotinic acetylcholine receptors restores nicotine-induced locomotion but not place conditioning. Genes Brain Behav (2008) 0.94
Molecules and circuits involved in nicotine addiction: The many faces of smoking. Neuropharmacology (2013) 0.94
Varenicline and cytisine diminish the dysphoric-like state associated with spontaneous nicotine withdrawal in rats. Neuropsychopharmacology (2013) 0.94
Bupropion inhibits the cellular effects of nicotine in the ventral tegmental area. Biochem Pharmacol (2007) 0.94
The nicotinic acetylcholine receptor partial agonist varenicline increases the ataxic and sedative-hypnotic effects of acute ethanol administration in C57BL/6J mice. Alcohol Clin Exp Res (2010) 0.94
The effects of nicotine, varenicline, and cytisine on schedule-controlled responding in mice: differences in α4β2 nicotinic receptor activation. Eur J Pharmacol (2010) 0.93
Effects of varenicline and bupropion on cognitive processes among nicotine-deprived smokers. Exp Clin Psychopharmacol (2011) 0.93
Varenicline potentiates alcohol-induced negative subjective responses and offsets impaired eye movements. Alcohol Clin Exp Res (2012) 0.93
Varenicline attenuates some of the subjective and physiological effects of intravenous nicotine in humans. Psychopharmacology (Berl) (2009) 0.92
Mechanism-based medication development for the treatment of nicotine dependence. Acta Pharmacol Sin (2009) 0.91
Unravelling the mechanism of action of NS9283, a positive allosteric modulator of (α4)3(β2)2 nicotinic ACh receptors. Br J Pharmacol (2013) 0.91
Preclinical evidence that activation of mesolimbic alpha 6 subunit containing nicotinic acetylcholine receptors supports nicotine addiction phenotype. Nicotine Tob Res (2012) 0.91
Neurophysiology of Nicotine Addiction. J Addict Res Ther (2011) 0.91
Cholinergic receptors: functional role of nicotinic ACh receptors in brain circuits and disease. Pflugers Arch (2013) 0.90
The nicotinic acetylcholine receptor as a target for antidepressant drug development. ScientificWorldJournal (2012) 0.90
Recent advances in gene manipulation and nicotinic acetylcholine receptor biology. Biochem Pharmacol (2011) 0.90
The Role of the Habenula in Nicotine Addiction. J Addict Res Ther (2011) 0.90
Tobacco smoking cessation management: integrating varenicline in current practice. Vasc Health Risk Manag (2008) 0.90
Abrogation of TGF beta signaling in mammary carcinomas recruits Gr-1+CD11b+ myeloid cells that promote metastasis. Cancer Cell (2008) 6.78
The adaptor Act1 is required for interleukin 17-dependent signaling associated with autoimmune and inflammatory disease. Nat Immunol (2007) 5.33
The growth factor progranulin binds to TNF receptors and is therapeutic against inflammatory arthritis in mice. Science (2011) 4.76
Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. Nat Genet (2013) 4.35
PTEN deletion enhances the regenerative ability of adult corticospinal neurons. Nat Neurosci (2010) 4.28
A role for VEGF as a negative regulator of pericyte function and vessel maturation. Nature (2008) 3.74
Functional nucleic acid sensors. Chem Rev (2009) 3.32
Reduced mitochondrial oxidative capacity and increased mitochondrial uncoupling impair myocardial energetics in obesity. Circulation (2005) 3.22
A colorimetric lead biosensor using DNAzyme-directed assembly of gold nanoparticles. J Am Chem Soc (2003) 2.77
Fast colorimetric sensing of adenosine and cocaine based on a general sensor design involving aptamers and nanoparticles. Angew Chem Int Ed Engl (2005) 2.45
Impaired cardiac efficiency and increased fatty acid oxidation in insulin-resistant ob/ob mouse hearts. Diabetes (2004) 2.39
The role of KRAS rs61764370 in invasive epithelial ovarian cancer: implications for clinical testing. Clin Cancer Res (2011) 2.09
A statistical framework for protein quantitation in bottom-up MS-based proteomics. Bioinformatics (2009) 2.07
Act1, a U-box E3 ubiquitin ligase for IL-17 signaling. Sci Signal (2009) 2.05
Partial agonists of the α3β4* neuronal nicotinic acetylcholine receptor reduce ethanol consumption and seeking in rats. Neuropsychopharmacology (2010) 1.99
Using personal glucose meters and functional DNA sensors to quantify a variety of analytical targets. Nat Chem (2011) 1.93
Contribution of impaired myocardial insulin signaling to mitochondrial dysfunction and oxidative stress in the heart. Circulation (2009) 1.91
Rationale, pharmacology and clinical efficacy of partial agonists of alpha4beta2 nACh receptors for smoking cessation. Trends Pharmacol Sci (2007) 1.88
Nicotinic acetylcholine receptors: from basic science to therapeutics. Pharmacol Ther (2012) 1.82
Epidermal growth factor receptor expression and gene copy number in the risk of oral cancer. Cancer Prev Res (Phila) (2010) 1.80
Time-dependent, protein-directed growth of gold nanoparticles within a single crystal of lysozyme. Nat Nanotechnol (2011) 1.77
Multiple roles of chemokine (C-C motif) ligand 2 in promoting prostate cancer growth. J Natl Cancer Inst (2010) 1.74
Rationally tuning the reduction potential of a single cupredoxin beyond the natural range. Nature (2009) 1.68
Mentoring. Linking student interests to science curricula. Science (2007) 1.68
Agonistic monoclonal antibodies potentiate tumorigenic and invasive activities of splicing variant of the RON receptor tyrosine kinase. Cancer Biol Ther (2006) 1.67
The critical role of epithelial-derived Act1 in IL-17- and IL-25-mediated pulmonary inflammation. J Immunol (2009) 1.67
Validation of the simplified criteria for diagnosis of autoimmune hepatitis in Chinese patients. J Hepatol (2010) 1.63
Dissecting metal ion-dependent folding and catalysis of a single DNAzyme. Nat Chem Biol (2007) 1.63
ABCB1 (MDR1) polymorphisms and ovarian cancer progression and survival: a comprehensive analysis from the Ovarian Cancer Association Consortium and The Cancer Genome Atlas. Gynecol Oncol (2013) 1.61
Genetic susceptibility to childhood acute lymphoblastic leukemia shows protection in Malay boys: results from the Malaysia-Singapore ALL Study Group. Leuk Res (2009) 1.60
Preparation of aptamer-linked gold nanoparticle purple aggregates for colorimetric sensing of analytes. Nat Protoc (2006) 1.60
Rational design of a structural and functional nitric oxide reductase. Nature (2009) 1.60
Inhibition of interleukin-6 with CNTO328, an anti-interleukin-6 monoclonal antibody, inhibits conversion of androgen-dependent prostate cancer to an androgen-independent phenotype in orchiectomized mice. Cancer Res (2006) 1.59
Bone morphogenetic protein-6 promotes osteoblastic prostate cancer bone metastases through a dual mechanism. Cancer Res (2005) 1.56
A catalytic beacon sensor for uranium with parts-per-trillion sensitivity and millionfold selectivity. Proc Natl Acad Sci U S A (2007) 1.56
Unique autonomic profile of the pulmonary veins and posterior left atrium. J Am Coll Cardiol (2007) 1.56
Soluble receptor activator of nuclear factor kappaB Fc diminishes prostate cancer progression in bone. Cancer Res (2003) 1.55
Antimicrobial susceptibility testing using high surface-to-volume ratio microchannels. Anal Chem (2010) 1.54
Accelerated color change of gold nanoparticles assembled by DNAzymes for simple and fast colorimetric Pb2+ detection. J Am Chem Soc (2004) 1.53
A modular microfluidic architecture for integrated biochemical analysis. Proc Natl Acad Sci U S A (2005) 1.52
Reversible cell-specific drug delivery with aptamer-functionalized liposomes. Angew Chem Int Ed Engl (2009) 1.50
Interleukin-1 (IL-1)-induced TAK1-dependent Versus MEKK3-dependent NFkappaB activation pathways bifurcate at IL-1 receptor-associated kinase modification. J Biol Chem (2006) 1.48
Platinum sensitivity-related germline polymorphism discovered via a cell-based approach and analysis of its association with outcome in ovarian cancer patients. Clin Cancer Res (2011) 1.47
An inhibitor of casein kinase I epsilon induces phase delays in circadian rhythms under free-running and entrained conditions. J Pharmacol Exp Ther (2007) 1.47
Competencies: a cure for pre-med curriculum. Science (2011) 1.47
Meta-analysis of the relationship between Parkinson disease and melanoma. Neurology (2011) 1.45
Tumour necrosis factor-α and its receptors in the beneficial effects of vagal stimulation after myocardial infarction in rats. Clin Exp Pharmacol Physiol (2011) 1.45
Inhibition of the striatum-enriched phosphodiesterase PDE10A: a novel approach to the treatment of psychosis. Neuropharmacology (2006) 1.44
Laser-layered microfabrication of spatially patterned functionalized tissue-engineering scaffolds. J Biomed Mater Res B Appl Biomater (2005) 1.44
Acute effects of atypical antipsychotics on whole-body insulin resistance in rats: implications for adverse metabolic effects. Neuropsychopharmacology (2006) 1.43
Pediatric video laryngoscope versus direct laryngoscope: a meta-analysis of randomized controlled trials. Paediatr Anaesth (2014) 1.42
Retracted Inhibition of rho-kinase by fasudil suppresses formation and progression of experimental abdominal aortic aneurysms. PLoS One (2013) 1.39
Retracted Integrated gene network analysis and text mining revealing PIK3R1 regulated by miR-127 in human bladder cancer. Eur J Med Res (2013) 1.39
Effects of norepinephrine on kidney in a swine model of cardiopulmonary resuscitation. Am J Emerg Med (2010) 1.39
A DNAzyme catalytic beacon sensor for paramagnetic Cu2+ ions in aqueous solution with high sensitivity and selectivity. J Am Chem Soc (2007) 1.39
Rapamycin inhibits osteoblast proliferation and differentiation in MC3T3-E1 cells and primary mouse bone marrow stromal cells. J Cell Biochem (2008) 1.38
A simple and sensitive "dipstick" test in serum based on lateral flow separation of aptamer-linked nanostructures. Angew Chem Int Ed Engl (2006) 1.37
Novel diagnostic biomarkers for prostate cancer. J Cancer (2010) 1.36
Immobilized nerve growth factor and microtopography have distinct effects on polarization versus axon elongation in hippocampal cells in culture. Biomaterials (2006) 1.36
Rational design of "turn-on" allosteric DNAzyme catalytic beacons for aqueous mercury ions with ultrahigh sensitivity and selectivity. Angew Chem Int Ed Engl (2007) 1.35
AAPS-FDA workshop white paper: microdialysis principles, application and regulatory perspectives. Pharm Res (2007) 1.35
Astragaloside IV ameliorates renal injury in streptozotocin-induced diabetic rats through inhibiting NF-κB-mediated inflammatory genes expression. Cytokine (2013) 1.35
CXCR6 induces prostate cancer progression by the AKT/mammalian target of rapamycin signaling pathway. Cancer Res (2008) 1.33
Reduction potential tuning of the blue copper center in Pseudomonas aeruginosa azurin by the axial methionine as probed by unnatural amino acids. J Am Chem Soc (2006) 1.33
Smoking, quitting, and psychiatric disease: a review. Neurosci Biobehav Rev (2011) 1.33
Adenosine-dependent assembly of aptazyme-functionalized gold nanoparticles and its application as a colorimetric biosensor. Anal Chem (2004) 1.30
Roles of glutamates and metal ions in a rationally designed nitric oxide reductase based on myoglobin. Proc Natl Acad Sci U S A (2010) 1.29
Endothelin-1 activates endothelial cell nitric-oxide synthase via heterotrimeric G-protein betagamma subunit signaling to protein jinase B/Akt. J Biol Chem (2003) 1.29
Improving fluorescent DNAzyme biosensors by combining inter- and intramolecular quenchers. Anal Chem (2003) 1.29
Highly sensitive and selective colorimetric sensors for uranyl (UO2(2+)): development and comparison of labeled and label-free DNAzyme-gold nanoparticle systems. J Am Chem Soc (2008) 1.28
MRI detection of thrombin with aptamer functionalized superparamagnetic iron oxide nanoparticles. Bioconjug Chem (2008) 1.26
Glioblastoma cells incorporate into tumor vasculature and contribute to vascular radioresistance. Int J Cancer (2010) 1.24
The alpha4beta2 nicotinic acetylcholine-receptor partial agonist varenicline inhibits both nicotine self-administration following repeated dosing and reinstatement of nicotine seeking in rats. Psychopharmacology (Berl) (2009) 1.24
FRET study of a trifluorophore-labeled DNAzyme. J Am Chem Soc (2002) 1.24
Sirt3 regulates metabolic flexibility of skeletal muscle through reversible enzymatic deacetylation. Diabetes (2013) 1.22
FoxO1 links insulin resistance to proinflammatory cytokine IL-1beta production in macrophages. Diabetes (2009) 1.22
A lead-dependent DNAzyme with a two-step mechanism. Biochemistry (2003) 1.22
3D printing and neurosurgery--ready for prime time? World Neurosurg (2013) 1.22
Oxygenated cembranoids from the cultured and wild-type soft corals Sinularia flexibilis. Chem Pharm Bull (Tokyo) (2009) 1.21
Nanoscale patterns of oligonucleotides formed by electrohydrodynamic jet printing with applications in biosensing and nanomaterials assembly. Nano Lett (2008) 1.21
Astragaloside IV, a novel antioxidant, prevents glucose-induced podocyte apoptosis in vitro and in vivo. PLoS One (2012) 1.21
The role of copper and protons in heme-copper oxidases: kinetic study of an engineered heme-copper center in myoglobin. Proc Natl Acad Sci U S A (2003) 1.20
Stimuli-responsive disassembly of nanoparticle aggregates for light-up colorimetric sensing. J Am Chem Soc (2005) 1.20
Activation of vascular endothelial growth factor receptor-1 sustains angiogenesis and Bcl-2 expression via the phosphatidylinositol 3-kinase pathway in endothelial cells. Diabetes (2003) 1.20
Functional polymorphisms in the TERT promoter are associated with risk of serous epithelial ovarian and breast cancers. PLoS One (2011) 1.20
Neutral thiol as a proximal ligand to ferrous heme iron: implications for heme proteins that lose cysteine thiolate ligation on reduction. Proc Natl Acad Sci U S A (2003) 1.20
The essential role of single Ig IL-1 receptor-related molecule/Toll IL-1R8 in regulation of Th2 immune response. J Immunol (2009) 1.19
A review of the clinical pharmacokinetics and pharmacodynamics of varenicline for smoking cessation. Clin Pharmacokinet (2010) 1.19
Varenicline has antidepressant-like activity in the forced swim test and augments sertraline's effect. Eur J Pharmacol (2009) 1.19
Toward an understanding of the molecular mechanism for successful blood feeding by coupling proteomics analysis with pharmacological testing of horsefly salivary glands. Mol Cell Proteomics (2007) 1.17
Arthroscopic Bankart repair combined with remplissage technique for the treatment of anterior shoulder instability with engaging Hill-Sachs lesion: a report of 49 cases with a minimum 2-year follow-up. Am J Sports Med (2011) 1.17
Microbial communities in the larval midgut of laboratory and field populations of cotton bollworm (Helicoverpa armigera). Can J Microbiol (2006) 1.16
Enhanced bioavailability of the poorly water-soluble drug fenofibrate by using liposomes containing a bile salt. Int J Pharm (2009) 1.16
Multimodality data integration in epilepsy. Int J Biomed Imaging (2007) 1.16
Probing the role of axial methionine in the blue copper center of azurin with unnatural amino acids. J Am Chem Soc (2003) 1.15
Formation of 3-halobenzyne: solvent effects and cycloaddition adducts. Org Lett (2004) 1.14
Molecular diagnostic and drug delivery agents based on aptamer-nanomaterial conjugates. Adv Drug Deliv Rev (2010) 1.14
Metalloproteins containing cytochrome, iron-sulfur, or copper redox centers. Chem Rev (2014) 1.13